About Gazyva/Gazyvaro Gazyva®/Gazyvaro® (obinutuzumab) is a humanised monoclonal antibody designed with a Type II anti-CD20 ...

ToltIQ today announced that H.I.G. Capital (“H.I.G.”), a leading global alternative asset management firm with $74 billion in assets under management, with a focus on middle market businesses, has ...

Francesca Smedberg has been appointed as Chief Product Officer (CPO) and she will be joining the Executive Management Team, of Enento Group Plc, effective 16 March 2026. She will report directly to ...

Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹ Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as ...

ARTEX Global Markets Wuhrstrasse 6, 9490, Vaduz LIECHTENSTEIN . ARTEX Market Update: Francis Bacon’s Self-Portrait (1972) doubles its low estimate, reaching £16,035,000 at Soth ...

Tero Aspinen, Member of the Executive Management Team and VP Middle East at QPR Software Plc, will leave the company to join Leaders Solutions, a long-standing partner of QPR. Leaders Solutions is a ...

Fentics Technology Limited, a London-based provider of asset–liability management (ALM) software for insurers, has been named the winner of “ALM Solution of the Year” at the InsuranceERM UK & Europe ...

Ebene, Mauritius, March 6, 2026 - While the trading community has often been seen as a "gentlemen’s club," this International Women’s Day, PU Prime is proud to spotlight a sto ...

EET. Nokia has published its Nokia in 2025 Annual Report and filed its Annual Report on Form 20-F for 2025 . Espoo, ...

Cylake  today announced its launch as a new cybersecurity company bringing complete, AI-native, data-driven protection to customers in a fully sovereign way—no public cloud required. The company was ...

Kemira has received a notification from Petri Castrén, Chief Financial Officer, of a transaction made with its financial instrument, according to the EU Market Abuse Regulation. Detailed information ...

At the maximally effective dose, there were no cases of vomiting and no treatment discontinuations due to gastrointestinal adverse events Basel, 05 March 2026 - Roche (SIX: RO, ROG; OTCQX: RHHBY) ...